### Edgar Filing: CTI BIOPHARMA CORP - Form 4

CTI BIOPHARMA CORP Form 4									
September 25, 2015									
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549Check this box if no longer subject to 							9PROVAL 3235-0287		
							January 31, 2005 average irs per . 0.5		
(Print or Type Responses)									
1. Name and Address of Reporting NUDELMAN PHILLIP M P	HD Symbol	er Name <b>and</b>		c	5. Relationship of Reporting Person(s) to Issuer				
(Last) (First) (Middle) 3. Date of Earliest Transaction				(Cho	(Check all applicable)				
(Month/Day/ 3101 WESTERN AVE, SUITE 600 09/23/2015			ransaction						
(Street) SEATTLE, WA 98121	Filed(Month/Day/Year)			1	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State)	(Zip) Tab	le I - Non-I	Derivative	Securities A	cquired, Disposed	of. or Beneficia	llv Owned		
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)		3. Transactio Code (Instr. 8) Code V	4. Securit nAcquired Disposed (Instr. 3, 4	ies (A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect		
Reminder: Report on a separate line	for each class of sec	urities benef	Perso inform	ns who res nation cont	or indirectly. pond to the colle ained in this forn ond unless the fo	n are not	SEC 1474 (9-02)		

required to respond unless the form displays a currently valid OMB control number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8.1
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	TransactionDerivative		Expiration Date	Underlying Securities	De
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	Sec
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Acquired (A)			(In

#### Edgar Filing: CTI BIOPHARMA CORP - Form 4

	Derivative Security		(D (In	or Disposed of (D) (Instr. 3, 4, and 5)						
			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	<u>(1)</u>	09/23/2015	А	79	9,618		(2)	(2)	Common Stock	79,618

### **Reporting Owners**

Reporting Owner Name / Address	Relationships							
reporting officer runner runn of	Director	10% Owner	Officer	Other				
NUDELMAN PHILLIP M PHD 3101 WESTERN AVE SUITE 600 SEATTLE, WA 98121	Х							
Signatures								
By: Louis A. Bianco, Attorney-in-fact For: Philip M.								

Nudelman

\*\*Signature of Reporting Person

09/25/2015

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each restricted stock unit represents the right to receive, at settlement, one share of CTIC common stock.
- (2) These restricted stock units are scheduled to vest on the date that is twelve months after the date of grant or, if earlier, the first annual meeting of CTIC's shareholders in 2016 at which one or more members of the CTIC Board of Directors are to be elected.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.